In an extremely preterm infant (<28 weeks gestation or <1000 g) with hypotension refractory to adequate volume expansion and first‑line catecholamine support, what is the recommended hydrocortisone dosing regimen and monitoring?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Hydrocortisone for Refractory Hypotension in Extremely Preterm Infants

For extremely preterm infants (<28 weeks or <1000g) with hypotension refractory to volume expansion and catecholamines, administer hydrocortisone 0.5 mg/kg every 12 hours for 9-12 days, followed by 0.25 mg/kg every 12 hours for 3 days as a taper.

Recommended Dosing Regimen

The most extensively studied and safest hydrocortisone regimen for this population is based on multiple randomized controlled trials in extremely low birth weight infants 1:

Initial Phase:

  • 0.5 mg/kg every 12 hours (total 1 mg/kg/day)
  • Duration: 9-12 days
  • Start within 48 hours of birth if hypotension develops

Taper Phase:

  • 0.25 mg/kg every 12 hours (total 0.5 mg/kg/day)
  • Duration: 3 days
  • Then discontinue

This regimen was used in the largest multicenter trial (n=360) and multiple supporting studies specifically in the 500-999g birth weight population 1.

Rationale for This Approach

Extremely preterm infants have relative adrenal insufficiency due to immature adrenal gland function, predisposing them to inadequate anti-inflammatory capability and poor hemodynamic stability during the first weeks of life 1. This physiologic basis supports early hydrocortisone use for refractory hypotension.

Critical distinction from dexamethasone: Unlike dexamethasone (which has been linked to adverse neurodevelopmental outcomes), hydrocortisone at these doses has shown no adverse effects on neurodevelopmental outcomes at 18-22 months corrected age 1. The largest trial showed similar rates of death or major neurodevelopmental impairment (52% vs 56% placebo), with actually favorable trends in cognitive outcomes (decreased incidence of MDI <70: 27% vs 37%) 1.

Clinical Monitoring

Hemodynamic monitoring:

  • Blood pressure every 15-30 minutes initially, then hourly once stable
  • Heart rate continuous monitoring
  • Urine output (target >1 mL/kg/hr)
  • Capillary refill and perfusion assessment

Metabolic monitoring:

  • Blood glucose every 4-6 hours (hydrocortisone can cause hyperglycemia)
  • Serum sodium and potassium daily
  • Watch for hyponatremia if concurrent mineralocorticoid effect

Gastrointestinal surveillance:

  • Abdominal examination every 4-6 hours
  • Critical caveat: Multiple trials were terminated early due to concerns about spontaneous gastrointestinal perforation 1
  • Hold feeds or advance cautiously during treatment
  • Maintain high index of suspicion for perforation (abdominal distension, discoloration, pneumoperitoneum on X-ray)

Important Caveats and Pitfalls

Avoid higher doses: The evidence specifically supports 1 mg/kg/day divided doses. Higher doses (2 mg/kg/day used in one trial) showed no additional benefit and historical high-dose regimens (25 mg/kg/day) were associated with harm 1.

GI perforation risk: This is the most serious complication. The risk appears highest when hydrocortisone is combined with indomethacin or ibuprofen for patent ductus arteriosus treatment. Avoid concurrent use if possible 1.

Timing matters: The evidence base is strongest for initiation within 48 hours of birth in infants requiring mechanical ventilation and vasopressor support 1.

Not for routine prophylaxis: While some studies showed improved survival without bronchopulmonary dysplasia, the overall benefit was inconsistent. Reserve hydrocortisone for infants with actual refractory hypotension requiring vasopressor support, not as routine prophylaxis 1.

Alternative Dosing Consideration

One trial used 2 mg/kg/day tapered to 0.75 mg/kg/day over 10 days in 501-1250g infants, but this study was also terminated early for GI perforation concerns and showed no significant benefit 1. The lower dose regimen (1 mg/kg/day) is preferred given similar efficacy with potentially better safety profile.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.